

Ligand Pharmaceuticals Missed Consensus Estimates
Ligand Pharmaceuticals (LGND) reported a loss of $2.21 per share on revenue of $45.33 million for the first quarter ended March 2025. The consensus earnings estimate was $0.14 per share on revenue of $39.39 million. The company missed consensus estimates by 1,678.57% while revenue grew 46.34% on a year-over-year basis.
The company said it continues to expect 2025 non-GAAP earnings of $6.00 to $6.25 per share on revenue of $180.0 million to $200.0 million. The current consensus earnings estimate is $6.14 per share on revenue of $192.69 million for the year ending December 31, 2025.
Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
-